Biogen International Neuroscience Gmbh

University Of Zürich

Biogen Idec Ma Inc.

Biogen Ma Inc.

University of California

Other

Curis, Inc.

Biogen Idec, Inc.

Paul H Weinreb

Jan Grimm

Shelia Marie Violette

Roger Nitsch

Christoph Hock

Kenneth J Simon

Alexey Alexandrovich Lugovskoy

Ellen A Garber

Fabio Montrasio

R Blake Pepinsky

Dean Sheppard

Dingyi Wen

Lihe Su

Andreas Weihofen

Maria Grazia Barenco Montrasio

Jean-Luc Baeriswyl

Omar Quintero-Monzon

Diane R Leone

Janaky Coomaraswamy

Jose William Saldanha

Timothy David Jones

Francis Joseph Carr

Werner Meier

Laura Silvian

Daniel H S Lee

Jane K Relton

Xinzhong Wang

Louise A Koopman

Herman W T Van Vlijmen

Anja Sibylle Tessarz

Russell Colyn Petter

Frederick Robbins Taylor

Jeffrey A Porter

Kevin P Williams

Herman Van Vlijmen

Feng Chen

Darren P Baker

Alphonse Galdes

Kathryn Strauch

Chenhui Zeng

Daniel Hs Lee

Daniel HS Lee

Provided are TAR DNA-binding protein of 43 kDa (TDP-43)-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these TDP-43 specific binding molecules. Assays, kits, and solid supports related to TDP-43-specific binding molecules, including polypeptides such as, human antibodies are also disclosed. The TDP-43-specific binding molecule, antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for TDP-43 targeted immunotherapy and diagnosis, respectively.

TDP-43 specific binding molecules

Provided are anti-human &#x3b1;-synuclein-specific binding molecules, e.g., antibodies or antiben-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human &#x3b1;-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human &#x3b1;-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for &#x3b1;-synuclein targeted immunotherapy and diagnosis, respectively.

Anti-alpha synuclein binding molecules

Humanized antibodies and antibody fragments thereof that bind to &#x3b1;v&#x3b2;6 are disclosed. Also disclosed are methods of using these antibodies and antibody fragments to treat or prevent &#x3b1;v&#x3b2;6-mediated diseases such as fibrosis and cancer.

Anti-alpha V beta 6 antibodies and uses thereof

Humanized antibodies and antibody fragments thereof that bind to &#x3b1;v&#x3b2;6 are disclosed. Also disclosed are methods of using these antibodies and antibody fragments to diagnose, treat, and/or prevent &#x3b1;v&#x3b2;6-mediated diseases such as acute tissue injury, fibrosis, and cancer.

Monoclonal antibodies that specifically bind to M.96. Also included are methods of using these antibodies to treat mammals having or at risk of having 006-mediated diseases, or to diagnose % Qmediated diseases.

[object Object]

Provided are human tau-specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for tau are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for tau targeted immunotherapy and diagnosis, respectively.

Human anti-tau antibodies

Provided are novel TAR DNA-binding proteins of 43 kDa ('TDP-43')-specific binding molecules including polypeptides such as human antibodies, as well as fragments, derivatives and variants thereof. Also provided are methods related to these TDP-43 specific binding molecules. Assays, kits, and solid supports related to TDP-43-specific binding molecules, including polypeptides such as, human antibodies are also disclosed. The TDP-43-specific binding molecule, antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for TDP-43 targeted immunotherapy and diagnosis, respectively.

Provided are anti-human &#x3b1;-synuclein-specific binding molecules, e.g., antibodies or antigen-binding fragments, variants or derivatives thereof, as methods related thereto. Further provided are anti-human &#x3b1;-synuclein binding molecules which bind to specific N-terminal and C-terminal epitopes on human &#x3b1;-synuclein. The binding molecules described herein can be used in pharmaceutical and diagnostic compositions for &#x3b1;-synuclein targeted immunotherapy and diagnosis, respectively.

Anti-&#x3b1; synuclein binding molecules

Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are Nogo receptor antagonist polynucleotides. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, nucleic acids encoding the same and antagonist polynucleotides.

Nogo receptor antagonists and methods of increasing neurite outgrowth

The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize &#x3b1;&#x3b2;integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-&#x3b1;&#x3b2;antibodies of the invention. The invention also relates to the identification of differential expression of the integrin &#x3b1;&#x3b2;on the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin &#x3b1;&#x3b2;.

Nogo receptor antagonists

Monoclonal antibodies that specifically bind to &#x25a1;v&#x25a1;&#x25a1;. Also included are methods of using these antibodies to treat mammals having or at risk of having &#x25a1;v&#x25a1;6-mediated diseases, or to diagnose &#x25a1;V&#x25a1;6-mediated diseases.

Growing community of inventors

Methuen, MA, United States of America

Paul H Weinreb